1 Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012;56 Suppl 1:S39 – S45.

2 Edmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine. 1967;46(2):119 –129.

3 Guirguis J, Chhatwal J, Dasarathy J, Rivas J , McMichael D , Nagy LE, et al. Clinical impact of alcohol -related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res. 2015;39(11):2085 –2094.

4 Tapper EB , Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999 -2016: observational study. BMJ. 2018;362:k2817.

5 Case A, Deaton A. Rising morbidity and mortality in midlife among white non -Hispanic Americans in the 21st century. Proc Natl Acad Sci USA. 2015;112(49):15078 –15083.

6 Peery AF , Crockett SD , Barritt AS , Dellon ES , Eluri S , Gangarosa LM, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology. 2015;149(7):1731 -1741.

7 Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524 -530.

8 Beste LA, Leipertz SL, Green PK, Dominitz JA , Ross D , Ioannou GN. Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001 –2013. Gastroenterology. 2015;149(6):1471 –1482.

9 Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ , et al. The High Burden of Alcoholic Cirrhosis in Privately Insured Persons in the United States. Hepatology. 2018;68(3):872 — 882.

10 Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160 –168.

11 Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.

12 Goldberg D, Ditah IC, Saeian K, Lalehzari M , Aronsohn A , Gorospe EC, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017;152(5):1090 –1099.

13 Chirapongsathorn S, Krittanawong C, Enders FT, Pendegraft R, Mara KC, Borah BJ, et al. Incidence and cost analysis of hospital admission and 30 -day readmission among patients with cirrhosis. Hepatology Communications. 2018;2(2):188 –198.

14 Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol -use disorders. Lancet. 2009(9682);373:2223 –2233.

15 Jinjuvadia R, Liangpunsakul S; Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium Trends in Alcoholic Hepatitis -related Hospitalizations, Financial Burden, and Mortality in the United States. J Clin Gastroenterol . 2015 ;49(6):506 — 511 .

16 Pang JX , Ross E , Borman MA , Zimmer S , Kaplan GG , Heitman SJ, et al. Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data. BMC Gastroenterol. 2015;15:116.

17 Sandahl TD , Jepsen P , Thomsen KL , Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999 -2008: a nationwide population based cohort study. J Hepatol. 2011;54(4):760 -764.

18 Sahlman P, Nissinen M, Pukkala E, Färkkilä M. Incidence, survival and cause -specific mortality in alcoholic liver disease: a population -based cohort study. Scand J Gastroenterol. 2016;51(8):961 -966.

19 Alavi M, Janjua NZ, Chong M, Grebely J , Aspinall EJ , Innes H, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. J Hepatol. 2018;6 8(3):393 –401.

20 Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM -5®). American Psychiatric Pub; 2013.

21 Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM -5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757 –766.

22 Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. Addiction. 1993;88(6):791 –804.

23 Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12 -Month Alcohol Use, High -Risk Drinking, and DSM -IV Alcohol Use Disorder in the United States, 2001 -2002 to 2012 -2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017; 74(9):911 -923.

24 Vaughn -Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of Perceived Stigma Among Patients with Cirrhosis. Dig Dis Sci . 2014;59(3):681 –686.

25 Ries RK, Fiellin DA, Miller SC, Saitz R. The ASAM Principles of Addiction Medicine. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2014.

26 https://www.niaaa.nih.gov/guide Accessed January 4, 2019.

27 US Preventive Services Task Force , Curry SJ , Krist AH , Owens DK , Barry MJ , Caughey AB, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;13;320(18):1899 -1909.

28 Conigrave KM, Saunders JB, Reznik RB. Predictive capacity of the AUDIT questionnaire for alcohol -related harm. Addiction. 1995;90(11):1479 –1485.

29 Bush K, Kivlahan DR, McDonell MB, Fihn SD , Bradley KA. The AUDIT alcohol consumption questions (AUDIT -C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med . 1998;158(16):1789 –1795.

30 Bradley KA, DeBenedetti AF, Volk RJ, Williams EC , Frank D , Kivlahan DR. AUDIT -C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208 –1217.

31 https://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide5_help_p.htm

32 Sheron N, Moore M, O’Brien W, Harris S , Roderick P. Feasibility of detection and intervention for alcohol -related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J Gen Pract . 2013;63(615):e698 –705.

33 Westwood G, Meredith P, Atkins S, Greengross P , Schmidt PE , Aspinall RJ. Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease. J Hepatol. 2017;67(3):559 –567.

34 Donnadieu -Rigole H, Olive L, Nalpas B, Winter A , Ursic -Bedoya J , Faure S, et al. Follow -Up of Alcohol Consumption After Liver Transplantation: Interest of an Addiction Team? Alcohol Clin Exp Res. 2017;41(1):165 –170.

35 Au DH, Kivlahan DR, Bryson CL, Blough D , Bradley KA. Alcohol screening scores and risk of hospitalizations for GI conditions in men. Alcohol Clin Exp Res. 2007;31(3):443 –451.

36 Jarvis M , Williams J , Hurford M , Lindsay D , Lincoln P , Giles L , et al. Appropriate Use of Drug Testing in Clinical Addiction Medicine. J Addict Med. 2017;11(3):163 -173.

37 https://doi.org/10.1176/appi.books.9781615371969 Accessed January 4, 2019.

38 DiMartini A. Alcohol Abuse and Liver Disease. John Wiley & Sons; 2016.

39 Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res. 2010;34(6):955 –967.

40 Conigrave KM, Davies P, Haber P, Whitfield JB. Traditional markers of excessive alcohol use. Addiction. 2003;98 Suppl 2:31 –43.

41 Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM , Horsfall LU , Johnson L, et al. BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate -deficient transferrin. Alcohol Clin Exp Res. 2013;37:1771 –1778.

42 Andresen -Streichert H, Beres Y, Weinmann W, Schröck A, Müller A, Skopp G, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int . 2017;30(6):611 -620.

43 Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in patients pre — and post -liver transplantation improves detection of alcohol consumption. Hepatology . 2011;54(5):1640 -1649.

44 Berlakovich GA , Soliman T , Freundorfer E , Windhager T , Bodingbauer M , Wamser P, et al. Pretransplant screening of sobriety with carbohydrate -deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int. 2004;17(10):617 -621.

45 DiMartini A , Day N , Lane T , Beisler AT , Dew MA , Anton R. Carbohydrate deficient transferrin in abstaining patients with end -stage liver disease. Alcohol Clin Exp Res. 2001;25(12):1729 -1733.

46 Stewart SH , Reuben A , Anton RF. Relationship of Abnormal Chromatographic Pattern for Carbohydrate -Deficient Transferrin with Severe Liver Disease. Alcohol Alcohol. 2017;52(1):24 -28.

47 Berlakovich GA , Windhager T , Freundorfer E , Lesch OM , Steininger R , Mühlbacher F. Carbohydrate deficient transferrin for detection of alcohol relapse after orthotopic liver transplantation for alcoholic cirrhosis. Transplantation. 1999;67(9):1231 -1235.

48 Allen JP , Wurst FM , Thon N , Litten RZ. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl. 2013;19(4):369 -376.

49 Walsham NE, Sherwood RA. Ethyl glucuronide. Ann Clin Biochem . 2012;49:110 –117.

50 Stewart SH, Koch DG, Burgess DM, Willner IR , Reuben A. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. Alcohol Clin Exp Res. 2013;37(1):150 – 155.

51 Nguyen VL, Haber PS, Seth D. Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini Review). Alcohol Clin Exp Res. 2018;42(2):238 –243.

52 Gnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res. 2012;36(9):1507 –1511.

53 Schröck A, Wurst FM, Thon N, Weinmann W. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test — C (AUDIT -C). Drug Alcohol Depend 2017;178:80 –86.

54 Wurst FM, Thon N, Aradottir S, Hartmann S , Wiesbeck GA , Lesch O, et al. Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self — reports. Addict Biol. 2010;15(1):88 –95.

55 Viel G, Boscolo -Berto R, Cecchetto G, Fais P , Nalesso A , Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta -analysis. Int J Mol Sci. 2012;13(11):14788 –14812.

56 Stewart SH, Reuben A, Brzezinski WA, Koch DG , Basile J , Randall PK, et al. Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol. 2009;44(5):464 –467.

57 Stewart SH, Law TL, Randall PK, Newman R. Phosphatidylethanol and alcohol consumption in reproductive age women. Alcohol Clin Exp Res. 2010;34(3):488 –492.

58 Simon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regul Toxicol Pharmacol. 2018;94:163 –171.

59 Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014;38(6):1706 –1711.

60 Miller WR, Rollnick S. Motivational Interviewing, Third Edition. Guilford Press; 2012.

61 https://alcoholtreatment.niaaa.nih.gov Accessed January 4, 2019.

62 Khan A, Tansel A, White DL, Kayani WT , Bano S , Lindsay J, et al. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2016;14(2):191 –202.

63 Willenbring ML, Olson DH. A Randomized Trial of Integrated Outpatient Treatment for Medically Ill Alcoholic Men. Arch Intern Med . 1999;159(16):1946 –1952.

64 Weinrieb RM, Van Horn DHA, Lynch KG, Lucey MR. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl . 2011;17(5):539 –547.

65 Kuchipudi V, Hobein K, Flickinger A, Iber FL. Failure of a 2 -hour motivational intervention to alter recurrent drinking behavior in alcoholics with gastrointestinal disease. J Stud Alcohol. 1990;51(4):356 –360.

66 Dieperink E, Fuller B, Isenhart C, McMaken K , Lenox R , Pocha C, et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction. 2014;109(11):1869 –1877.

67 Dieperink E, Ho SB, Heit S, Durfee JM , Thuras P , Willenbring ML. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics. 2010;51:149 –156.

68 Proeschold -Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, et al. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci. 2012;57:1083 –1091.

69 Drumright LN, Hagan H, Thomas DL, Latka MH , Golub ET , Garfein RS, et al. Predictors and effects of alcohol use on liver function among young HCV -infected injection drug users in a behavioral intervention. J Hepatol. 2011;55(1):45 –52.

70 Klimas J, Tobin H, Field CA, O’Gorman CS , Glynn LG , Keenan E, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev . 2014;12:CD009269.

71 Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65(3):618 –630.

72 Johnson BA, Ait -Daoud N, Bowden CL, DiClemente CC , Roache JD , Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361(9370):1677 –1685.

73 Johnson BA, Rosenthal N, Capece JA, Wiegand F , Mao L , Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641 –1651.

74 Johnson BA, Roache JD, Javors MA , DiClemente CC , Cloninger CR , Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284(8):963 –971.

75 de Bejczy A, Löf E, Walther L, Guterstam J , Hammarberg A , Asanovska G, et al. Varenicline for treatment of alcohol dependence: a randomized, placebo -controlled trial. Alcohol Clin Exp Res. 2015;39(11):2189 –2199.

76 Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561 –564.

77 Yamini D, Lee SH, Avanesyan A, Walter M, Runyon B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol. 2014;49(4):453 –456.

78 Addolorato G, Leggio L, Ferrulli A, Cardone S , Vonghia L , Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol -dependent patients with liver cirrhosis: randomised, double -blind controlled study. The Lancet. 2007;370(9603):1915 –1922.

79 Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta -analysis. Drug Alcohol Rev. 2010;29(4):437 — 445.

80 https://health.gov/dietaryguidelines/2015/guidelines/ Accessed January 4, 2019.

81 https://www.niaaa.nih.gov/alcohol -health/overview -alcohol -consumption/moderate -binge -drinking Accessed January 4, 2019.

82 https://www.samhsa.gov/sites/default/files/alcohol -use -facts -resources -fact -sheet.pdf Accessed January 4, 2019.

83 Wood AM , Kaptoge S , Butterworth AS , Willeit P , Warnakula S , Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual — participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513 -1523.

84 GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990 — 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015 -1035.

85 Seitz HK, Bataller R, Cortez -Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.

86 Savolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res. 1993;17(5):1112 -1117.

87 Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845 — 850.

88 Becker U, Deis A, Sorensen TI, Gronbaek M, Borch -Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025 -1029.

89 Becker U, Grønbaek M, Johansen D , Sørensen TI. Lower risk for alcohol -induced cirrhosis in wine drinkers. Hepatology. 2002; 35(4):868 -875.

90 Askgaard G, Grønbæk M, Kjær MS, Tjønneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol. 2015;62(5):1061 -1067.

91 Dam MK, Flensborg -Madsen T, Eliasen M, Becker U, Tolstrup JS. Smoking and risk of liver cirrhosis: a population -based cohort study. Scand J Gastroenterol. 2013;48(5):585 -591.

92 Åberg F, Helenius -Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: a population -based cohort study. Liver Int. 2017;37(9):1373 -1381

93 Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136(10):1248 -1257.

94 Stroffolini T, Cotticelli G, Medda E, Niosi M, Del Vecchio -Blanco C, Addolorato G, et al. Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int. 2010;30(6):867 -870.

95 Wadhawan M, Anand AC. Coffee and Liver Disease. J Clin Exp Hepatol. 2016; 6(1):40 -46.

96 Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta -analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016;43(5):562 — 574.

97 Liangpunsakul S, Beaudoin JJ, Shah VH, Puri P, Sanyal AJ, Kamath PS, et al. Interaction between the patatin -like phospholipase domain -containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatol Commun. 2017;2(1):29 -34.

98 Edenberg HJ, Foroud T. Genetics and alcoholism. Nat Rev Gastroenterol Hepatol. 2013;10(8):487 — 494.

99 Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ -specific endpoints of alcoholism. Alcohol Clin Exp Res. 1996;20:1528 -1533.

100 Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol -related pathology. Proc Nutr Soc. 2004; 63(1):49 -63.

101 Zeng T, Guo FF, Zhang CL, Song FY, Zhao XL, Xie KQ. Roles of cytochrome P4502E1 gene polymorphisms and the risks of alcoholic liver disease: a meta -analysis. PLoS One. 2013;8(1):e54188

102 Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res. 2001;25(8):1181 -1187.

103 Levy R, Catana AM, Durbin -Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res. 2015;39(3):566 -574.

104 Salameh H, Raff E, Erwin A, Seth D, Nischalke HD, Falleti E, et al. PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. Am J Gastroenterol. 2015;110(6):846 — 856.

105 Buch S, Stickel F, Trépo E, Way M , Herrmann A , Nischalke HD , et al. A genome -wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol -related cirrhosis. Nat Genet. 2015; 47(12):1443 -1448.

106 Atkinson SR , Way MJ , McQuillin A , Morgan MY , Thursz MR. Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. J Hepatol. 2017;67(1):120 -127.

107 Beaudoin JJ, Long N, Liangpunsakul S, Puri P, Kamath PS, Shah V ;TREAT Consortium. An exploratory genome — wide analysis of genetic risk for alcoholic hepatitis. Scand J Gastroenterol. 2017; 52:1263 -1269.

108 Stickel F, Moreno C, Hampe J, Morgan MY. The genetics of alcohol dependence and alcohol — related liver disease. J Hepatol. 2017; 66:195 -211.

109 Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol -related cirrhosis. Am J Gastroenterol. 2018;113(10):1475 -1483.

110 Abul -Husn NS , Cheng X , Li AH , Xin Y , Schurmann C , Stevis P, et al. A Protein -Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378(12):1096 — 1106.

111 Ajmera VH , Terrault NA , Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65(6):2090 -2099.

112 Åberg F , Helenius -Hietala J , Puukka P , Färkkilä M , Jula A. Interaction between alcohol consumption and metabolic syndrom e in predicting severe liver disease in the general population. Hepatology. 2018;67(6):2141 -2149.

113 Schwarzinger M , Baillot S , Yazdanpanah Y , Rehm J , Mallet V. Contribution o f alcohol use disorders on the burden of chronic hepatitis C in France, 2008 -2013: A nationwide retrospective cohort study. J Hepatol. 2017;67(3):454 -461.

114 Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122(2):281 -289.

115 National Center on Addiction and Substance Abuse at Columbia University: Missed Opportunity: National Survey of Primary Care Physicians and Patients on Substance Abuse. April 2000. Available at: http://www.casacolumbia.org/addiction -research/reports/national -survey -primary -care -physicians — patients -substance -abuse. Accessed January 4, 2019.

116 Hatton J, Burton A, Nash H, Munn E, Burgoyne L, Sheron N. Drinking patterns, dependency and life -time drinking history in alcohol -related liver disease. Addiction . 2009;104(4):587 -592.

117 Lucey MR, Connor JT, Boyer TD, Henderson JM, Rikkers LF; DIVERT Study Group. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. Am J Gastroenterol. 2008;103(7):1698 -1706.

118 Whitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, et al. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol. 2018;66:1 -7.

119 Tapper EB, Lok ASF. Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med. 2017;7;377(23):2296 -2297.

120 Reeder SB, Cruite I, Hamilton G, Sirlin CB, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34(4):729 –749.

121 Baptista A, Bianchi L, de Groote J. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet . 1981;1(8222):707 -711.

122 Im GY, Lucey MR. Practical Concerns and Controversies in the Management of Alcoholic Hepatitis. Gastroenterol Hepatol (N Y). 2016;12(8):478 -489.

123 Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785 -790.

124 Bissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, et al. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology. 2007;66(2):555 –563.

125 Hanouneh IA , Zein NN , Cikach F , Dababneh L , Grove D , Alkhouri N , et al. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol. 2014;12(3):516 — 523.

126 Gelsi E, Dainese R, Truchi R, Mariné -Barjoan E, Anty R, Autuori M, et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res. 2011;35(3):566 — 570.

127 Thiele M, Detlefsen S, Sevelsted Møller L, Madsen BS, Fuglsang Hansen J, Fialla AD, et al. Transient and 2 -Dimensional Shear -Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. Gastroenterology. 2016;150(1):123 -133.

128 Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test Vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology. 2018;154(5):1369 -1379.

129 Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Me d . 2009;360(26):2758 -2769.

130 Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology . 1978;75:193 -199.

131 Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut. 2007;56(12):1743 –1746.

132 Dunn W, Jamil LH, Brown LS, Wiesner RH , Kim WR , Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353 –358.

133 Dominguez M, Rincón D, Abraldes JG, Miquel R , Colmenero J , Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103(11):2747 –2756.

134 Merion RM , Wolfe RA , Dykstra DM , Leichtman AB , Gillespie B , Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003;9(1):12 -18.

135 Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated wit h steroids. Hepatology. 2007;45(6):1348 –1354.

136 Garcia -Saenz -de -Sicilia M, Duvoor C, Altamirano J, Chavez -Araujo R, Prado V, de Lourdes Candolo -Martinelli A, et al. A Day -4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis. Am J Gastroenterol. 2017;112(2):306 -315.

137 Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O’Grady J, et al. Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology. 2015;149(2):398 -406.

138 Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte -Rojo A, Louvet A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146(5):1231 -1239.

139 Horvath B, Allende D, Xie H, Guirguis J, Jeung J, Lapinski J, et al. Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis. Alcohol Clin Exp Res . 2017;41(9):1568 — 1573.

140 Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, et al. Combination of Gene Expression Signature and Model for End -Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018;154(4):965 -975.

141 Altamirano J , Fagundes C , Dominguez M , García E , Michelena J , Cárdenas A, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10(1):65 -71.

142 Sujan R , Cruz -Lemini M , Altamirano J , Simonetto D , Maiwall R , Axley P , et al. A Validated Score Predicts Acute Kidney Injury and Survival in Patients with Alcoholic Hepatitis: A Multicentric International Prospective Cohort Study. Liver Transpl. 2018;24(12):1655 -1664.

143 Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol . 2012;56 Suppl 1:S39 -S45.

144 Michelena J, Altamirano J, Abraldes JG, Affò S, Morales -Ibanez O, Sancho -Bru P, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015; 62(3):762 -772.

145 Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva -Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology . 2009;137(2):541 -548.

146 Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, et al. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection -Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. Gastroenterology . 2017;152(5):1068 -1077.

147 Michelena J, Altamirano J, Abraldes JG, Affò S, Morales -Ibanez O, Sancho -Bru P, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology . 2015;62(3):762 -772.

148 Atkinson SR, Way MJ, McQuillin A, Morgan MY, Thursz MR. Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. J Hepatol. 2017;67(1):120 -127.

149 Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology. 2017;66(5):1464 -1473.

150 Altamirano J, López -Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long -term survival. Hepatology. 2017;66(6):1842 -1853.

151 Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619 -1628.

152 Lucey MR, Connor JT, Boyer TD, Henderson JM , Rikkers LF ; DIVERT Study Group. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. Am J Gastroenterol. 2008;103:1698 –1706.

153 Verrill C, Markham H, Templeton A, Carr NJ, Sheron N, et al. Alcohol -related cirrhosis—early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009;104(5):768 – 774.

154 Potts JR, Goubet S, Heneghan MA, Verma S et al. Determinants of long -term outcome in severe alcoholic hepatitis. Aliment. Pharmacol. Ther. 2013;38(6):584 –595.

155 Mendenhall CL, Tosch T, Weesner RE, Garcia -Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein -calorie malnutrition. Am J Clin Nutr. 1986 43:213 -218.

156 Plauth M , Cabré E , Riggio O , Assis -Camilo M , Pirlich M , Kondrup J ; DGEM (German Society for Nutritional Medicine), et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr. 2006;25(2):285 -294.

157 Antar R, Wong P, Ghali P. A meta -analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012; 26(7):463 -467.

158 Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therap y in cirrhosis or alcoholic hepatitis: a systematic review and meta -analysis. Liver Int. 2015; 35(9):2072 -2078.

159 Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology. 2016; 150(4):903 -910.

160 Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Antioxidant supplements for liver diseases. Cochrane Database Syst Rev. 2011;16;:CD007749.

161 Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial. J Hepatol. 2006; 44(4):784 -790.

162 Dupont B, Dao T, Joubert C, Dupont -Lucas C, Gloro R, Nguyen -Khac E, et al. Randomised clinical trial: enteral nutrition does not improve the long -term outcome of alcoholic cirrhotic patients with jaundice. Aliment Pharmacol Ther. 2012; 35(10):1166 -1174.

163 Lieber SR, Rice JP, Lucey MR, Bataller R. Controversies in clinical trials for alcoholic hepatitis. J Hepatol . 2018;68(3):586 -592.

164 Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato -Biliary Group systematic review with meta -analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27(12):1167 -1178.

165 Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta -analysis adjusting for confounding variables. Gut. 1995;37(1):113 -118.

166 Pavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev 2017;11:CD001511.

167 Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short -term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol . 2002;36(4):480 -487.

168 Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short -term survival in patients with severe alcoholic hepatitis: meta -analysis of individual patient data. Gut . 2011;60(2):255 — 260.

169 Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo — a Meta -analysis of Individual Data From Controlled Trials. Gastroenterology. 2018;155(2):458 -468.

170 O’Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Hepatology. 2010;51(1):307 — 328.

171 Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res. 1995;19(3):635 –641.

172 https://clinicaltrials.gov/ct2/show/NCT02281929. Accessed January 6, 2019.

173 Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis.N Engl J Med. 2011;365(19):1790 — 1800.

174 Gustot T, Maillart E, Bocci M, Surin R, Trépo E, Degré D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol . 2014;60(2):267 — 274.

175 Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, et al. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection -Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. Gastroenterology . 2017;152(5):1068 -1077.

176 Parker R, Im G, Jones F, Hernández OP, Nahas J, Kumar A, et al. Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study. J Gastroenterol . 2017;52(11):1192 -1200.

177 Rudler M, Mouri S, Charlotte F, Lebray P, Capocci R, Benosman H, et al. Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. J Hepatol . 2015;62(4):816 — 821.

178 Nguyen -Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N -acetylcysteine in severe alcoholic hepatitis. N Engl J Med . 2011;365(19):1781 –1789.

179 Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N -acetylcysteine. Lancet. 1977;2(8035):432 — 434.

180 Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N — acetylcysteine improves transplant -free survival in early stage non -acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856 -864.

181 Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta -analysis . Gastroenterology. 2015;149(4):958 -970.

182 Spahr L, Lambert JF, Rubbia -Brandt L, Chalandon Y, Frossard JL, Giostra E, et al. Granulocyte — colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008;48(1):221 –229.

183 Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony — stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109(9):1417 –1423.

184 Moreau R, Rautou PE. G -CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol. 2014;109(9):1424 –1426.

185 Philips CA , Pande A , Shasthry SM , Jamwal KD , Khillan V , Chandel SS , et al. Healthy Donor Fecal Microbiota Transplantation in Steroid -Ineligible Severe Alcoholic Hepatitis: A Pilot Study. Clin Gastroenterol Hepatol. 2017;15(4):600 -602.

186 Higuera -de la Tijera F, Servín -Caamaño AI , Serralde -Zúñiga AE , Cruz -Herrera J, Pérez -Torres E, Abdo -Francis JM, et al. Metadoxine improves the three — and six -month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015;21(16):4975 -4985.

187 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short -term survival in severe acute alcoholic hepatitis: a double -blind, placebo -controlled trial. Gastroenterology. 2000;119(6):1637 -1648.

188 McHutchison JG, Runyon BA, Draguesku JO, Cominelli F. Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology. 1991;14:96A.

189 Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013; 310(10):1033 -1041.

190 Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thévenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non -responders to corticosteroids. J Hepatol. 2008;48(3):465 -470.

191 Naveau S, Chollet -Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al; Foie -Alcool group of the Association Française pour l’Etude du Foie. A double -blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis . Hepatology. 2004;39(5):1390 — 1397.

192 Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double — blinded, placebo -controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis . Gastroenterology. 2008;135(6):1953 -1960.

193 Thompson J , Jones N , Al -Khafaji A , Malik S , Reich D , Munoz S , et al;VTI -208 Study Group. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Liver Transpl. 2018;24(3):380 -393.

194 Rambaldi A , Gluud C. S -adenosyl — L — methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2001;(4):CD002235.

195 Mezey E, Potter JJ, Rennie -Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis . J Hepatol. 2004;40(1):40 -46.

196 Trinchet JC , Balkau B , Poupon RE , Heintzmann F , Callard P , Gotheil C, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology. 1992;15(1):76 -81.

197 Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short -term effects on liver function. Am J Gastroenterol. 1991;86(9):1200 -1208.

198 Fede G , Germani G , Gluud C , Gurusamy KS , Burroughs AK. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2011;(6):CD002800.

199 Singal AK , Kamath PS , Gores GJ , Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12(4):555 -564.

200 Szabo G. Clinical Trial Design for Alcoholic Hepatitis. Semin Liver Dis. 2017;37(4):332 -342.

201 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113(11):1649 -1659.

202 Cholankeril G, Ahmed A. Alcoholic Liver Disease replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356 -1358.

203 UNOS. UNOS Donation & Transplantation Data [online], http://unos.org/donation/index.php?topic=data (2013).

204 [No authors listed]. National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research. Hepatology. 1984;4(Suppl 1),1S -110S.

205 Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547 -555.

206 Lucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol. 2014;11(5):300 -307.

207 Volk ML Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med 2011;155(8):503 -508.

208 Moss AH, Siegler M. Should alcoholics compete equally for liver transplantation? JAMA. 1991;265:1295 -1298.

209 Veldt BJ , Lainé F , Guillygomarc’h A, Lauvin L, Boudjema K, Messner M, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002;36(1):93 -98.

210 Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, et al.; TRANSCIAL Study Group. Immediate listing for liver transplantation versus standard care for Child -Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med. 2009;150(3):153 — 161.

211 Nagai S , Chau LC , Schilke RE , Safwan M , Rizzari M , Collins K , et al. Effects of Allocating Livers for Transplantation Based on Model for End -Stage Liver Disease -Sodium Scores on Patient Outcomes. Gastroenterology. 2018;155(5):1451 -1462.

212 Beresford TP, Lucey MR. Towards Standardizing the Alcoholism Evaluation Of Potential Liver Transplant Recipients. Alcohol Alcohol. 2018;53(2):135 -144.

213 Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg . 1997;3(3):220 -226.

214 Beresford TP in Liver Transplantation and the Alcoholic Patient. (eds Lucey MR, Merion RM & Beresford TP) 29 -49 (Cambridge Press, 1994).

215 Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Disease. Liver Transpl Surg 1997;3:628 -637.

216 Leong J, Im GY. Evaluation and selection of the patient with alcoholic liver disease for liver transplant. Clin Liver Dis 2012;16(4):851 -863.

217 Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17(7):751 -759.

218 Yates WR, Martin M, LaBrecque D, Hillebrand D, Voigt M, Pfab D. A model to examine the validity of the 6 -month abstinence criterion for liver transplantation. Alcohol Clin Exp Res. 1998;22(2):513 — 517.

219 Mathurin P, Lucey MR. Alcohol, liver disease, and transplantation: shifting attitudes and new understanding leads to changes in practice. Curr Opin Organ Transplant . 2018;23(2):175 -179.

220 Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults : 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144 -65.

221 Rodrigue JR , Hanto DW , Curry MP. The Alcohol Relapse Risk Assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant. Prog Transplant. 2013;23(4):310 — 318.

222 Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre -transplant candidates. Psychosomatics. 2012;53(2):123 -132.

223 Beresford TP, Turcotte JG, Merion R, Burtch G, Blow FC, Campbell D, et al. A rational approach to liver transplantation for the alcoholic. Psychosomatics . 1990;31:241 -254.

224 Yates WR , Booth BM , Reed DA , Brown K , Masterson BJ. Descriptive and predictive validity of a high -risk alcoholism relapse model. J Stud Alcohol. 1993;54(6):645 -51.

225 De Gottardi A, Spahr L, Gelez P, Morard I , Mentha G , Guillaud O, et al. A simple score for predicting alcohol relapse after liver transplantation. Arch Intern Med. 2007;167(11):1183 -1188.

226 Beresford TP. Psychiatric assessment. In: Lucey MR, Merion RM, Beresford TP (Eds). Liver transplantation and the alcoholic patient: medical, surgical and psychosocial Issues. New York, NY: Cambridge University Press;1994:96 -112.

227 Schaubel DE , Guidinger MK , Tome S , Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology. 2009;50(2):400 -406.

228 Weinrieb RM, Van Horn DH, McLellan AT, Alterman AI, Calarco JS, O’Brien CP, et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics. 2001;42:110 -116.

229 Dumortier J, Dharancy S, Cannesson A, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol. 2015;110(8):1160 -1166 .

230 DiMartini A, Dew MA, Day N, Fitzgerald MG, Jones BL, DeVera, ME et al. Trajectories of Alcohol Consumption Following Liver Transplantation. Am J Transplant. 2010;10(10):2305 –2312.

231 Fleming MF, Smith MJ, Oslakovic E, Lucey MR, Vue JX, Al -Saden P et al. Phosphatidylethanol (PEth) detects moderate to heavy alcohol use in liver transplant recipients. Alcohol Clin Exp Res. 2017;41(4):857 -862.

232 Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in patients pre — and post -liver transplantation improves detection of alcohol consumption. Hepatology. 2011;54(5):1640 -1649.

233 Piano S, Marchioro L, Gola E, Rosi S, Morando F, Cavallin M, et al. Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available. Liver Transpl. 2014;20(7):815 -822.

234 Faure S, Herrero A, Jung B, Duny Y, Daures JP, Mura T, et al. Excessive alcohol consumption after liver transplantation impacts on long -term survival, whatever the primary indication. J Hepatol. 2012;57(2):306 -312.

235 Wells JT, Said A, Agni R, Tome S, Hughes S, Dureja P, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl. 2007;13(12):1728 -1735.

236 Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology. 2012;55(5):1398 -1405.

237 Im GY, Kim -Schluger L, Shenoy A, Schubert E, Goel A, Friedman SL, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States— A Single -Center Experience. Am J Transplant. 2016;16(3):841 -849.

238 Lee BP, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, et al. Three -year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis . Ann Surg. 2017;265(1):20 -29.

239 Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, et al. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018;155(2):422 -430.

240 Lee BP , Vittinghoff E , Hsu C , Han H , Therapondos G , Fix OK, et al. Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post -Liver Transplant Score. Hepatology. 2019 Apr;69(4):1477 -1487.

241 Thursz M, Allison M. Liver transplantation for alcoholic hepatitis: Being consistent about where to set the bar. Liver Transpl. 2018;24(6):733 -734.

242 Dureja P , Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52(5):759 -764.

243 Puri P, Cholankeril G, Myint TY, Goel A, Sarin SK, Harper AM, et al. Early Liver Transplantation is a Viable Treatment Option in Severe Acute Alcoholic Hepatitis . Alcohol Alcohol. 2018;53(6):716 -718.

244 Bangaru S , Pedersen MR , MacConmara MP , Singal AG , Mufti AR . Survey of Liver Transplantation Practices for Severe Acute Alcoholic Hepatitis. Liver Transpl. 2018;24(10):1357 -1362.